Infliximab as a possible treatment for the hemorrhagic type of Crohn's disease

Journal of Gastroenterology

Volumn 39, Issue 3, 2004, Pages 284-287

  Tsujikawa, Tomoyuki ^a   Nezu, Riichiro ^b   Andoh, Akira ^a   Saotome, Takao ^a   Araki, Yoshio ^a   Ishizuka, Yoshiyuki ^a   Sasaki, Masaya ^a   Koyama, Shigeki ^a   Fujiyama, Yoshihide ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Crohn's disease; Gastrointestinal bleeding; Infliximab

Indexed keywords

INFLIXIMAB; SALAZOSULFAPYRIDINE; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; COLON ANASTOMOSIS; COLON RESECTION; CROHN DISEASE; DRUG INFUSION; EMERGENCY SURGERY; ENTERIC FEEDING; GASTROINTESTINAL HEMORRHAGE; HEMATOCHEZIA; HOSPITAL ADMISSION; HUMAN; INTESTINE RESECTION; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; REOPERATION; TREATMENT OUTCOME; ULCER HEALING; PATHOLOGY;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; TREATMENT OUTCOME;

EID: 1942536183     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00535-003-1290-9     Document Type: Article

References (18)

1. Robert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn's disease. Ann Surg 1991;213:207-11.
2. Cirocco WC, Reilly JC, Rusin LC. Life-threatening hemorrhage and exsanguination from Crohn's disease. Report of four cases. Dis Colon Rectum 1995;38:85-95.
3. Driver CP, Anderson DN, Keenan RA. Massive intestinal bleeding in association with Crohn's disease. J R Coll Surg Edinb 1996;41:152-4.
4. Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ, Alexander GL, Balm RK, et al. Acute major gastrointestinal hemorrhage in inflammatory bowel disease. Gastrointest Endsc 1999;49:153-7.
5. Sans M, Llach J, Bordas JM, Andreu V, Gines A, Mondelo F, et al. Life-threatening hemorrhage: an unusual form of presentation of Crohn's disease treated with endoscopic injection sclerotherapy. Endoscopy 1998;30:S83-4.
6. Belaiche J, Louis E, D'Haens G, Cabooter M, Naegels S, De Vos M, et al. Acute lower gastrointestinal bleeding in Crohn's disease: characteristics of a unique series of 34 patients. Belgian IBD Research Group. Am J Gastroenterol 1999;94:2177-81.
7. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
8. Rizzello F, Gionchetti P, Venturi A, Morselli C, Campieri M. The management of refractory Crohn's disease. Aliment Pharmacol Ther 2002;16:40-7.
9. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, Fuentes D, Dieguez A, Deschamps EM, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002; 97:2350-6.
10. Homan WP, Tang CK, Thorbjarnarson B. Acute massive hemorrhage from intestinal Crohn disease. Report of seven cases and review of the literature. Arch Surg 1976;111:901-5.
11. McGarrity TJ, Manasse JS, Koch KL, Weidner WA. Crohn's disease and massive lower gastrointestinal bleeding: angiographic appearance and two case reports. Am J Gastroenterol 1987;82: 1096-9.
12. Renison DM, Forouhar FA, Levine JB, Breiter JR. Filiform polyposis of the colon presenting as massive hemorrhage: an uncommon complication of Crohn's disease. Am J Gastroenterol 1983; 78:413-6.
13. Mellor JA, Chandler GN, Chapman AH, Irving HC. Massive gastrointestinal bleeding in Crohn's disease: successful control by intra-arterial vasopressin infusion. Gut 1982;23:872-4.
14. Blomberg B. Endoscopic treatment modalities in inflammatory bowel disease. Endoscopy 1992;24:578-81.
15. Wettstein AR, Meagher AP. Thalidomide in Crohn's disease. Lancet 1997;350:1445-6.
16. Belaiche J, Louis E. Severe lower gastrointestinal bleeding in Crohn's disease: successful control with infliximab. Am J Gastroenterol 2002;97:3210-1.
17. Vatay A, Bene L, Kovacs A, Prohaszka Z, Szalai C, Romics L, et al. Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease. Immunogenetics 2003;55:247-52.
18. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.